Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19792176 | 1.00 | ACACB (0.40) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL25730009 | 0.94 | ACACB (0.39) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL25922603 | 0.92 | ACACB (0.38) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL18328129 | 0.90 | ACACB (0.39) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL20553993 | 0.87 | CHRM2 (0.41) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL20553992 | 0.87 | CHRM2 (0.41) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL38656021 | 0.84 | ACACB (0.38) | ACACBCHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL25234631 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL14310674 | 0.81 | CHRM2 (0.37) | CHRM2CHRM1CHRM3EPHX2USP2 | |
| SCHEMBL8936177 | 0.81 | CHRM2 (0.37) | ACACBCHRM2CHRM1CHRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019144912-A1 | β-LACTAMASE INHIBITOR AND USE THEREOF | 苏州信诺维医药科技有限公司 | 2019-08-01 | — | — | WO | disclosed |
| US-9718807-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160340345-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2015-08-20 | — | — | US | disclosed |
| US-9056860-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | ACACB 1861/4885CHRM2 4873/4885CHRM1 4799/4885 |
| US-20160340345-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | ACACB 1861/4885CHRM2 4873/4885CHRM1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.